SweetValueLab
Write for us

Quest Diagnostics Incorporated — Wall Street Analyst Estimates & Price Targets

DGX
NYSEHealthcareMedical - Diagnostics & ResearchCIK 0001022079questdiagnostics.comAbout DGX
Last close · Oct 16, 2026235.00−4.15 (−1.74%)
Market cap$25.9B

6 firms' latest targets, last 90 days: median $257.50 ($245.00–$260.00), 10% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$175$200$225$250NovJan 2026MarMayJulSep2025-10-17 · UBS: $1902025-10-17 · Mizuho Securities: $2102025-10-21 · Jefferies: $2152025-10-21 · Leerink Partners: $2102025-10-22 · Truist: $2052025-10-22 · Morgan Stanley: $2072025-10-22 · Barclays: $1952025-10-27 · Piper Sandler: $2002026-01-30 · Barclays: $2102026-02-10 · Jefferies: $2202026-02-11 · UBS: $2102026-02-11 · Truist: $2202026-02-11 · Evercore ISI: $2202026-02-11 · Baird: $2192026-02-12 · Mizuho Securities: $2352026-04-08 · Evercore ISI: $2102026-04-21 · Evercore ISI: $2252026-04-21 · Jefferies: $2252026-07-13 · Baird: $2362026-07-23 · Barclays: $2502026-07-23 · Jefferies: $2452026-07-24 · UBS: $2322026-07-24 · Baird: $2552026-07-29 · Argus Research: $2602026-09-08 · UBS: $2452026-09-21 · Truist: $2602026-10-07 · Barclays: $260
$175$200$225$250NovFebMayAug

Each firm's latest target

last 90 days · 6 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-10-07Barclays$260.00$250.00▲ 4%+14%+11%
2026-09-21Truist$260.00$220.00▲ 18%+5%+11%
2026-09-08UBS$245.00$232.00▲ 6%+4%+4%
2026-07-29Argus Research$260.00——+10%+11%
2026-07-24Baird$255.00$236.00▲ 8%+12%+9%
2026-07-23Jefferies$245.00$225.00▲ 9%+8%+4%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2023reported$9.3B-6%$7.49-6%est. $9.2B+0%est. $8.7112
2024reported$9.9B+7%$7.69+3%est. $9.8B+0%est. $8.9012
2025reported$11.0B+12%$8.75+14%est. $11.0B+0%est. $9.818
2026$12.0B+9%$11.20+14%$12.0B–$12.1B$11.17–$11.2413
2027$12.6B+5%$12.04+8%$12.5B–$12.8B$11.80–$12.3213
2028$13.1B+4%$13.07+9%$12.9B–$13.3B$12.13–$14.1512
2029$13.8B+5%$14.71+12%$13.7B–$14.0B$14.53–$14.9710
2030$11.6B-16%$14.82+1%$11.5B–$11.7B$14.65–$15.086
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.